January 19th 2024
Benjamin Garmezy, MD, discusses key considerations for the selection of frontline treatment regimens in clear cell renal cell carcinoma.
November 22nd 2023
Benjamin Garmezy, MD, discusses the treatment of patients with cancer in the community care setting, highlighting the need to include those from this population in enrollment to clinical trials.
June 19th 2023
Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year.
April 14th 2023
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.
April 7th 2023
Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.
A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.
March 31st 2023
Experts on renal cell carcinoma discuss post-progression treatment options for RCC.
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.
March 24th 2023
Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.
Benjamin Garmezy, MD, presents the case of a 67-year-old man diagnosed with advanced renal cell carcinoma.
March 17th 2023
Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, open the discussion with an overview of renal cell carcinoma.
March 14th 2023
Precision medicine and personalized medicine are 2 concepts that have pushed their way to the forefront of oncology practice.